These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8880873)

  • 1. The plasminogen activation system in tumour invasion and metastasis.
    de Vries TJ; van Muijen GN; Ruiter DJ
    Pathol Res Pract; 1996 Jul; 192(7):718-33. PubMed ID: 8880873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
    J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
    Choong PF; Nadesapillai AP
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
    Halámková J; Kiss I; Tomášek J; Pavlovský Z; Tuček S; Penka M
    Vnitr Lek; 2012 Feb; 58(2):129-34. PubMed ID: 22463093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-dependent cell surface proteolysis and cancer.
    Blasi F; Verde P
    Semin Cancer Biol; 1990 Apr; 1(2):117-26. PubMed ID: 2151734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High tPA-expression in primary melanoma of the limb correlates with good prognosis.
    Ferrier CM; Suciu S; van Geloof WL; Straatman H; Eggermont AM; Koops HS; Kroon BB; Lejeune FJ; Kleeberg UR; van Muijen GN; Ruiter DJ
    Br J Cancer; 2000 Nov; 83(10):1351-9. PubMed ID: 11044361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the plasminogen activation system in angiogenesis and metastasis.
    Rabbani SA; Mazar AP
    Surg Oncol Clin N Am; 2001 Apr; 10(2):393-415, x. PubMed ID: 11382594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors involved in the plasminogen activation system in human breast tumours.
    Damjanovich L; Turzó C; Adány R
    Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
    Ito Y; Takeda T; Kobayashi T; Wakasugi E; Tamaki Y; Umeshita K; Monden T; Shimano T; Monden M
    Anticancer Res; 1996; 16(1):81-9. PubMed ID: 8615674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of urokinase on cell proliferation and invasion.
    Binder BR
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):717-20. PubMed ID: 1966799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
    Schmitt M; Jänicke F; Graeff H
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
    Jankun J; Merrick HW; Goldblatt PJ
    J Cell Biochem; 1993 Oct; 53(2):135-44. PubMed ID: 8227186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
    Fazioli F; Blasi F
    Trends Pharmacol Sci; 1994 Jan; 15(1):25-9. PubMed ID: 8140655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of protease-mediated tumor invasiveness.
    Blasi F
    J Surg Oncol Suppl; 1993; 3():21-3. PubMed ID: 8503981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
    Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
    Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
    Durand MK; Bødker JS; Christensen A; Dupont DM; Hansen M; Jensen JK; Kjelgaard S; Mathiasen L; Pedersen KE; Skeldal S; Wind T; Andreasen PA
    Thromb Haemost; 2004 Mar; 91(3):438-49. PubMed ID: 14983218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.